First quarter results 2024
April 23, 2024 | Basel, Switzerland
Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.4 MB)
Interim financial report (PDF 0.4 MB)
Download the podcast (MP3 30 MB)
Download the presentation (PDF 6.0 MB)
Novartis Q1 2024 impact and sustainability update (PDF 1.4 MB)
Investors event calendar
View recent presentations and learn more about upcoming events.
May 15, 2024
Bank of America Healthcare Conference
Las Vegas, USA
Environmental, Social and Governance (ESG)
Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.
ESG updates: April 2024 (PDF 1.0 MB) | February 2024 (PDF 0.6 MB) | November 2023 (PDF 1.0 MB) | August 2023 (PDF 0.3 MB)
Latest updates: Impact & Health Equity (PDF 9.9 MB) | Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Reporting and transparency hub
Read our regulatory filings; policies, codes and guidelines that govern our activities; and environmental, social and governance (ESG) disclosures.
Media releases
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Pulse updates
Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland